PDE6D

Across TCGA pan-cancer cohorts, PDE6D Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PDE6D data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher PDE6D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PDE6D expression acts as an unfavorable survival marker.

SKCM, PRAD, and LUAD are the cancer types where PDE6D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	II,III,IV	0.174	0.731	<.001	11	view →
PRAD	DFS	Median	All	0.545	0.935	<.001	6	view →
LUAD	OS	Median	All	0.276	0.697	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PDE6D–SKCM (OS)

Open the SKCM breakdown →